文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

胸段硬膜外镇痛与急性胰腺炎死亡率:多中心倾向性分析

Thoracic Epidural Analgesia and Mortality in Acute Pancreatitis: A Multicenter Propensity Analysis.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论多中心回顾性队列显示,ICU急性胰腺炎患者接受胸段硬膜外镇痛后30天死亡率低于匹配的未接受者(2% vs 17%)。

该多中心回顾性观察性队列研究纳入法国和比利时17个ICU在2009年6月至2014年3月间收治的1303例急性胰腺炎患者,主要暴露为胸段硬膜外镇痛 versus 不使用硬膜外镇痛的标准治疗,主要结局为30天死亡率。212例在30天内死亡,46例使用了硬膜外镇痛。未校正分析显示硬膜外镇痛与死亡率降低相关(4% vs 22%,p=0.003);校正与死亡率相关的基线变量后,硬膜外镇痛仍是30天死亡率的独立预测因素(校正OR 0.10,95%CI 0.02-0.49,p=0.004);倾向性评分匹配后,接受硬膜外镇痛的患者30天全因死亡风险显著低于未接受者(2% vs 17%,p=0.01)。作者结论认为,在重症急性胰腺炎患者中,接受硬膜外镇痛者30天死亡率低于可比的未接受者,这些发现支持继续研究硬膜外镇痛作为急性胰腺炎治疗干预。

要点

  • 在17个ICU的1303例急性胰腺炎患者中,46例使用胸段硬膜外镇痛,其未校正30天死亡率为4%,未使用者为22%(p=0.003)。
  • 校正与死亡率相关的基线变量后,胸段硬膜外镇痛是30天死亡率的独立预测因素(校正OR 0.10,95%CI 0.02-0.49,p=0.004)。
  • 倾向性评分匹配后,接受胸段硬膜外镇痛者30天全因死亡率为2%,匹配的未接受者为17%(p=0.01)。
  • 作者认为这些发现支持继续研究胸段硬膜外镇痛作为急性胰腺炎的治疗干预,而非确立其常规使用。

适用人群与场景

  • 2009年6月至2014年3月间入住法国和比利时17个ICU的急性胰腺炎患者,共1303例。

处置流程与药物剂量

  • 主要暴露为胸段硬膜外镇痛 versus 不使用硬膜外镇痛的标准化治疗;原文未报告硬膜外镇痛的具体药物、剂量、给药方案及疗程。

研究设计与关键结果

  • 研究类型为多中心回顾性观察性队列研究,纳入17个法国和比利时ICU的1303例急性胰腺炎患者,主要暴露为胸段硬膜外镇痛 versus 不使用硬膜外镇痛的标准治疗,主要结局为30天死亡率。
  • 1303例中212例在30天内死亡,46例使用了硬膜外镇痛。
  • 未校正分析:硬膜外镇痛组30天死亡率为4%,未使用组为22%(p=0.003)。
  • 校正与死亡率相关的基线变量后,硬膜外镇痛仍是30天死亡率的独立预测因素(校正OR 0.10,95%CI 0.02-0.49,p=0.004)。
  • 倾向性评分分析:接受硬膜外镇痛的患者30天全因死亡风险显著低于匹配的未接受者(2% vs 17%,p=0.01)。

证据类型、等级与局限

  • 证据类型:多中心回顾性观察性队列研究,采用倾向性评分分析控制治疗分配偏倚和预后失衡。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在重症急性胰腺炎患者中,接受胸段硬膜外镇痛者30天死亡率低于可比的未接受者;这些发现支持继续研究胸段硬膜外镇痛作为急性胰腺炎的治疗干预。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Recent preclinical and clinical data suggest that thoracic epidural analgesia, a technique primarily aimed at decreasing pain, might exert anti-inflammatory effects, enhance splanchnic and pancreatic blood flow during acute pancreatitis; however, the influence of epidural analgesia on mortality remains under investigated in this setting. This study was therefore designed to assess the impact of epidural analgesia on mortality in ICU patients with acute pancreatitis.

DESIGN: Multicenter retrospective, observational, cohort study.

SETTING: Seventeen French and Belgian ICUs.

PATIENTS: All patients admitted to with acute pancreatitis between June 2009 and March 2014.

INTERVENTIONS: The primary exposure was thoracic epidural analgesia versus standard care without epidural analgesia. The primary outcome was 30-day mortality. Propensity analyses were used to control for bias in treatment assignment and prognostic imbalances.

MEASUREMENTS AND MAIN RESULTS: One thousand three ICU patients with acute pancreatitis were enrolled, of whom 212 died within 30 days. Epidural analgesia was used in 46 patients and was associated with reduced mortality in unadjusted analyses (4% vs. 22%; p = 0.003). After adjustment for baseline variables associated with mortality, epidural analgesia was still an independent predictor of 30-day mortality (adjusted odds ratio, 0.10; [95% CI, 0.02-0.49]; p = 0.004). Using propensity score analysis, the risk of all-cause 30-day mortality in patients with acute pancreatitis receiving epidural analgesia was significantly lower than that in matched patients who did not receive epidural analgesia (2% vs. 17%; p = 0.01).

CONCLUSIONS: Among critically ill patients with acute pancreatitis, mortality at 30 days was lower in patients who received epidural analgesia than in comparable patients who did not. These findings support ongoing research on the use of epidural analgesia as a therapeutic intervention in acute pancreatitis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Jabaudon M, Belhadj-Tahar N, Rimmelé T, et al. Thoracic Epidural Analgesia and Mortality in Acute Pancreatitis: A Multicenter Propensity Analysis. Crit Care Med. 2018. PMID: 29194144. doi:10.1097/CCM.0000000000002874

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。